CJC-1295 + Ipamorelin and Tesamorelin + Ipamorelin: GHRH blends compared

Two GHRH analogues and one secretagogue

Blends that pair a growth hormone releasing factor analogue with ipamorelin appear in reagent catalogues more and more often. At first glance they look alike: two peptides in one vial, a lyophilised powder and a single preparation protocol. The differences start in the molecular structure, in the way each component acts on the pituitary and in the research questions each blend can answer. This overview sorts out the two variants: CJC-1295 + ipamorelin and tesamorelin + ipamorelin. That makes it easier to choose the reagent that fits the planned experiment.

Why GHRH is combined with ipamorelin

The growth hormone axis relies on several linked signals. The first comes from GHRH, growth hormone releasing hormone, which acts on the GHRH receptor of somatotroph cells in the pituitary gland. The second is ghrelin and its receptor GHS-R, the target of secretagogues such as ipamorelin. Both routes lead to growth hormone (GH) release, but they enter the cell by different pathways. That is why researchers often ask whether stimulating both at once gives a result different from the sum of the two separate effects.

Combining two components in one lyophilisate simplifies preparation, but it does not remove the need for controls. Each component has to be described separately, and the result has to be interpreted in light of both pathways.

CJC-1295 (no DAC) and ipamorelin

CJC-1295 without DAC is a GRF(1-29) analogue, a modified version of the first 29 residues of growth hormone releasing factor, with changes that increase its stability in solution. The DAC version differs by a linker that binds the molecule to blood albumin. The blend uses the variant without the linker. This matters when you plan how long a solution can be worked with and when you compare results with the DAC version.

Ipamorelin is a short, synthetic pentapeptide and an agonist of the GHS-R receptor. The literature describes it as a secretagogue with high selectivity. Its small size keeps it a clearly separate component within the blend, even when the two are analysed together.

Tesamorelin and ipamorelin

Tesamorelin is a modified GHRH analogue based on the natural growth hormone releasing factor sequence. Its N-terminus carries a trans-3-hexenoic acid residue, and the molecule contains 44 amino acid residues. Tesamorelin has been studied clinically, which makes it easier to compare with published data on its structure and its behaviour in experimental systems.

In this variant, ipamorelin works just as it does in the CJC-1295 blend, as a GHS-R agonist. The difference therefore lies mainly in the GHRH analogue, not in the secretagogue. It is worth keeping this in mind when you read results from different sources, because the same secretagogue name does not mean the whole experimental setup is identical. The GHRH analogue used and its concentration matter just as much.

Comparison in one place

Feature	CJC-1295 + ipamorelin	Tesamorelin + ipamorelin
GHRH analogue	GRF(1-29) with stabilising modifications	GHRH-based, 44 residues, N-terminus with a trans-3-hexenoic acid residue
Secretagogue	ipamorelin (pentapeptide, GHS-R)	ipamorelin (pentapeptide, GHS-R)
Form	lyophilised	lyophilised
Variants	5 mg + 5 mg, 10 mg + 10 mg	5 mg + 5 mg, 10 mg + 5 mg
Purity	≥ 99% (HPLC), mass confirmed by MS	≥ 99% (HPLC), mass confirmed by MS

Both products differ mainly in their GHRH analogue and in the available quantities. The secretagogue is the same in both.

How to choose a variant for your research question

The first question concerns what you want to compare. If the project focuses on the stability of a GHRH analogue in solution, and on how the version without a linker behaves next to the DAC version, the CJC-1295 blend is a natural starting point. If the interest lies in the role of the fuller GHRH sequence and the N-terminal modification, tesamorelin is the better choice.

The second question concerns scale. The larger variant (10 mg + 10 mg for CJC-1295, 10 mg + 5 mg for tesamorelin) allows a longer series of experiments without opening the vial often. A smaller pack suits a pilot study while the protocol is still taking shape.

Designing comparisons

A blend does not replace control groups. A well planned project uses four arms: a control with buffer alone, ipamorelin on its own, the GHRH analogue on its own and the blend. Only such a layout shows whether an effect comes from one pathway or from their interaction.

From the start, write down the assessment criteria: which parameters will be measured, at what intervals and in which units. Without this, a comparison of two blends can mislead, because differences in scale may come from unequal sample preparation rather than from the molecules themselves. It is also good practice to record every reconstitution in the lab journal together with the reagent batch.

In in vitro models, rising cAMP levels and GH release have been reported in pituitary cell cultures. In animal models, changes in GH and IGF-1 levels have been described. The result depends on concentration, incubation time and the model used, so every set of conditions has to be documented and repeated.

Lab work

Storage

Keep the lyophilised powder at -20 °C, tightly sealed, away from light and moisture. Before opening, let the vial reach room temperature so that water vapour does not condense on the powder. Once reconstituted, store the solution at 2-8 °C and avoid repeated freezing and thawing. Split larger volumes into aliquots before freezing.

Reconstitution

Work according to your research protocol and aseptic practice. Bacteriostatic water is the most common solvent. For peptides with weaker solubility, some protocols use a dilute acetic acid as a pre-solvent and then bring the solution up with water. You can calculate the solvent volume and the final concentration in the concentration calculator. Record the result together with the batch number and the reconstitution date, so the experiment can be reproduced.

What you get in the shop

Each vial contains lyophilised powder with purity of 99% or higher, confirmed by HPLC, and its molecular mass is verified by mass spectrometry (MS). Orders leave within 24 hours. In Poland, parcels go to an InPost parcel locker, and across Europe DPD delivers them.